The Technical AnalystExchange: JKT Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
PT Merck Tbk Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.76% IDR3 990.00
America/New_York / 3 mai 2024 @ 05:08
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 787 520 mill |
| EPS: | 397.80 |
| P/E: | 10.03 |
| Earnings Date: | May 29, 2024 |
| SharesOutstanding: | 448.00 mill |
| Avg Daily Volume: | 0.0624 mill |
| RATING 2024-05-03 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.15x |
| Company: PE 10.03 | sector: PE 65.62 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.63x |
| Company: PE 10.03 | industry: PE 16.03 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
IDR3 346.84 (-16.12%) IDR-643.16 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
IDR 3 926.81 - 4 053.19 ( +/- 1.58%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | IDR3 990.00 (0.76% ) |
| Volume | 0.0238 mill |
| Avg. Vol. | 0.0624 mill |
| % of Avg. Vol | 38.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MERK.JK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MERK.JK
PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. It operates through three segments: Biopharma, Consumer Health, and Others. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in discovering, developing, manufacturing, and marketing pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders comprising hyperthyroidism and hypothyroidism. In addition, it leases and manages properties. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is headquartered in East Jakarta, Indonesia. PT Merck Tbk is a subsidiary of Merck Holding GmbH.